摘要
目的探讨阿托伐他汀治疗急性缺血性脑卒中的临床疗效和安全性。方法选取我院收治的80例急性缺血性脑卒中患者为研究对象,随机分为试验组和对照组,各40例。两组患者均给予常规治疗,对照组患者在常规治疗基础上给予口服肠溶阿斯匹林片治疗。试验组患者在对照组基础上,给予口服阿托伐他汀治疗。比较两组患者的临床疗效、治疗前、后血脂水平及不良反应发生情况。结果试验组患者的总有效率为90.00%,显著高于对照组的62.50%(P<0.05)。治疗后,试验组患者的TG、TC、HDL-C和LDL-C水平明显优于治疗前和对照组(P<0.05)。试验组患者不良反应总发生率为5.00%,显著低于对照组的20.00%(P<0.05)。结论阿托伐他汀治疗急性缺血性脑卒中临床效果显著,且不良反应轻微,值得临床推广应用。
Objective To assess the efficacy and safety of atorvastatin for treating acute ischemic stroke. Methods A total of 80 acute ischemic stroke patients admitted in our hospital were selected randomly divided into the experimental group and control group, with 40 cases in each group. All the patients received routine treatment, the patients in the control group were given aspirin tablet on the basis of routine treatment, and the intervention group was treated with atorvastatin based on the control group. The clinical effect, blood lipid levels and adverse reactions were compared between the two groups. Results The total effective rate of the experiment group was 90.00%, which was much higher than 62.50% of the control group （P〈0.05）. After treatment, the levels of TG, TC, HDL-C and LDL-C in the experimental group were better than those before treatment and those in the control group （P〈0.05）. The total incidence rate of adverse reactions of the experimental group was 5.00%, which was lower than 20.00% of the control group （P〈0.05）. Conclusion Atorvastatin has significant efficacy for treating acute ischemic stroke and has few adverse reactions, which deserves to be applied in clinic.
出处
《临床医学研究与实践》
2017年第28期29-30,共2页
Clinical Research and Practice
